SureTrader
Interactive Brokers Advertisement
SureTrader
Home > Boards > US Listed > Biotechs >

Rexahn Pharmaceuticals, Inc. (RNN)

RNN RSS Feed
Add RNN Price Alert      Hide Sticky   Hide Intro
Moderator: beambe, DorianGray
Search This Board: 
Last Post: 6/16/2017 2:13:54 AM - Followers: 225 - Board type: Free - Posts Today: 0



   
 



   http://www.rexahn.com/cms/    

    http://finance.yahoo.com/q/ks?s=RNN

       

About

Rexahn Pharmaceuticals Inc. (NYSE MKT: RNN) is a clinical stage biopharmaceutical company focused on developing best-in-class therapeutics for the treatment of cancer. Rexahn’s clinical development programs directly target specific proteins that are selectively expressed in human cancer cells, resulting in increased efficacy and reduced toxicity. In preclinical studies these drug candidates are effective against multiple drug resistant cancers and have shown to increase the effectiveness of various FDA approved cancer treatments. Rexahn is also developing specific biomarker tests that will help identify which patients will be most responsive to its treatments. The Company’s nanotechnology-based drug delivery system has shown it can make FDA approved chemotherapy drugs more effective.

Our clinical development pipeline consists of three novel compounds:

Archexin® is a unique anti-sense drug candidate that specifically targets the cancer cell signaling protein Akt-1. Archexin is the only specific inhibitor of Akt-1 in clinical development. The activated form of Akt-1, which is involved in cancer cell growth, survival, angiogenesis, and drug resistance, has been shown to be present or elevated in more than 12 different human cancer cell lines, including pancreatic and renal cell carcinoma. By inhibiting Akt-1, Archexin has shown to inhibit the growth of human renal cell carcinoma cell lines and exhibit a longer survival benefit in the human renal cell carcinoma animal xenograft model. Thus, while Akt-1 is a very specific anti-cancer target, it may have broad therapeutic potential across multiple types of cancer.

RX-3117 is a next generation, orally bioavailable nucleoside analog that is activated (phosphorylated) by the enzyme Uridine Cytidine Kinase 2 (UCK2) and inhibits both DNA and RNA synthesis which induces apoptotic cell death of tumor cells. UCK2 is overexpressed in multiple human tumors, but has a very limited presence in normal tissues. This unique specificity for cancer cells may lead to an improved efficacy and safety profile in cancer patients. This profile differs from existing nucleoside compounds (such as the widely used chemotherapy gemcitabine), which are activated by the enzyme DCK which is expressed in both cancer cell and in normal healthy tissue leading to significant toxicities at therapeutic doses. RX-3117 has demonstrated broad spectrum anti-tumor activity against 100 different human cancer cell lines (including Non-Small Cell Lung Cancer (NSCLC), breast, ovarian, pancreas, colon, renal, brain, bladder, cervical) and efficacy in 17 different mouse xenograft models (including colorectal, non-small cell lung, pancreatic and renal cell carcinoma) superior to that of gemcitabine.

Supinoxin (RX-5902) is an orally administered, first-in-class, small molecule inhibitor of phosphorylated-p68 (P-p68). P-p68, which is selectively expressed in cancer cells and is absent in normal tissue, increases the activity of multiple cancer related genes including cyclin D1, c-jun and c-myc, and plays a role in tumor progression and metastasis. Over-expression of P-p68 has been observed in solid tumors, such as melanoma, colon, ovarian and lung.

These clinical development programs are part of a growing oncology drug pipeline that consists of highly differentiated and exciting anti-cancer compounds.

Our strategy is to continue building a significant clinical development pipeline of innovative therapies that we will commercialize on our own or with other pharmaceutical partners. Rexahn’s powerful discovery engine and differentiated product pipeline provide the opportunity for a high value generating biopharmaceutical company.

 

 Rexahn  Pipeline

 

Management Team



Peter Suzdak, Ph.D.
Chief Executive Officer 

Dr. Peter Suzdak joined Rexahn Pharmaceuticals in February 2013. Dr. Suzdak has over 25 years of diverse experience, including several management positions, in the pharmaceutical industry. Most recently, Dr. Suzdak was Chief Scientific Officer of Corridor Pharmaceuticals, a company developing small molecule compounds to treat pulmonary and vascular disorders. Prior to Corridor Pharmacueitcals, he was co-Founder, Chief Executive Officer and Chief Scientific Officer of Cardioxyl Pharmaceuticals, a company focused on therapies for the treatment of cardiovascular disease. Previous to Cardioxyl Pharmaceuticals, he was President and Chief Executive Officer of Artesian Therapeutics, a company engaged in the development of small molecule therapeutics for cardiovascular diseases. Dr. Suzdak’s experience also includes his position as Senior Vice President of Research and Development of Guilford Pharmaceuticals, a company that developed therapeutics and diagnostics for neurological diseases and cancer, and as Director of Neurobiology for Novo Nordisk. Dr. Suzdak holds a Ph.D. in pharmacology and toxicology from the University of Connecticut.

Rick Soni, MBA
President and Chief Operating Officer

Rick Soni joined Rexahn in 2008 with over 20 years of sales, marketing, product planning and business development experience in the pharmaceutical industry. Prior to joining Rexahn, Mr. Soni held leadership roles at Otsuka America Pharmaceuticals, Inc., with responsibility for commercial development, corporate strategy and execution of licensing and acquisition of therapeutics, diagnostics and medical devices. Previously, Mr. Soni has held a variety of management positions at Novartis and Schering-Plough. Mr. Soni has a BS from the University of Wisconsin-Madison and an MBA from Fairleigh Dickinson University.

Tae Heum (Ted) Jeong, D. Mgt.
Sr. Vice President  and Chief Financial Officer

Dr. Jeong has been Chief Financial Officer of Rexahn Pharmaceuticals since 2002. He oversees all aspects of capital raising, accounting, operations, and corporate development for Rexahn. He is also responsible for investor relations, and played a key role in Rexahn’s 2008 listing on the New York Stock Exchange (NYSE) AMEX. For the past 16 years, he has extensive experience in venture capital and investment banking industry that includes role at Hyundai Venture Investment Corporation where he managed the Biotechnology investment team. Dr. Jeong holds a Doctor of Management from University of Maryland and an M.S. in Finance from Johns Hopkins University




ANALYST COVERAGE
 
Roth Capital Partners, LLC
      Joseph Pantginis, Ph.D.
646-358-1907

jpantginis@roth.com

Maxim Group, LLC
Echo He, MD, Ph.D.
212-895-3718

ehe@maximgrp.com

H. C. Wainwright & Co., LLC
Andrew Fein
212-356-0546

afein@hcwco.com   


INVESTOR RELATIONSThe Trout Group LLC
Tricia Truehart
(646) 378-2953
ttruehart@troutgroup.com

RNN
Current Price
Volume:
Bid Ask Day's Range
  • 1D
  • 1M
  • 2M
  • 3M
  • 6M
  • 1Y
  • 2Y
  • 3Y
  • 5Y
RNN News: Securities Registration Statement (simplified Form) (s-3/a) 06/23/2017 04:31:27 PM
RNN News: Current Report Filing (8-k) 06/12/2017 04:38:03 PM
RNN News: Prospectus Filed Pursuant to Rule 424(b)(5) (424b5) 06/08/2017 04:52:25 PM
RNN News: Current Report Filing (8-k) 06/07/2017 08:59:43 AM
RNN News: Securities Registration Statement (simplified Form) (s-3) 05/26/2017 04:24:06 PM
PostSubject
#3347  Sticky Note Repost - Updated pipeline chart, as you can DorianGray 03/27/17 11:44:15 PM
#3692   They've withheld Archexin data. It should have BioManRandy 06/16/17 02:13:54 AM
#3691   What would make u think it would be ttubular 06/15/17 05:43:03 PM
#3690   Really! Lol. Pittkid 06/15/17 04:08:56 PM
#3689   Archexin data should be released this Monday or BioManRandy 06/15/17 03:40:36 PM
#3688   Rinse and repeat. Down it goes under a slmlrd 06/12/17 09:59:59 AM
#3687   So the warrants for this offering are exercisable Woulfe 06/07/17 09:17:47 AM
#3686   $3.30 offering no shorts 06/07/17 09:17:00 AM
#3685   Very good update on rx3117 n we And ttubular 06/05/17 01:20:18 PM
#3684   Fear selling on the morning. Raid. I expect Woulfe 06/05/17 09:54:59 AM
#3683   GM RNN. Let's break 5 today and keep no shorts 06/05/17 08:39:25 AM
#3682   Indeed! There are a few biopharm companies that could n3m3sis 06/05/17 07:46:09 AM
#3681   Fantastic data! RNN attracting worldwide attention on the gipper 06/05/17 07:29:51 AM
#3680   Rexahn Pharmaceuticals Presents Preliminary Efficacy Data from the n3m3sis 06/04/17 05:55:47 PM
#3679   An offering is coming very soon to take Woulfe 06/04/17 02:15:44 PM
#3678   All positive news http://investors.rexahn.com/common/mobile/iphone/releasedetai Roesi84 06/04/17 01:40:37 PM
#3677   Indeed!!Cant wait !Long and strong Rodney213 06/03/17 02:58:23 PM
#3676   Yesterdays action revealed lots of interested parties following the gipper 06/03/17 11:33:53 AM
#3675   Wall was put up at $1.30 and price no shorts 06/02/17 03:16:27 PM
#3674   Hate when I miss the opportunity to buy Lone Wolf 06/02/17 01:22:03 PM
#3673   Long positions with RNN may also like the Stevm 06/02/17 12:16:12 PM
#3672   They are presenting RX-3117 phase 2a preliminary data no shorts 06/02/17 12:07:36 PM
#3671   I thought it was 6/6 ? Rodney213 06/02/17 11:57:45 AM
#3670   Looking good. People buying in anticipation of 6/4 data no shorts 06/02/17 09:27:52 AM
#3669   I'm a bit surprised it's that high. BLUEVOODU 05/31/17 09:48:26 AM
#3668   Strange ask this morning now $4.48 was $4.20 no shorts 05/31/17 08:39:13 AM
#3667   I wasn't 100% sure of the difference between BLUEVOODU 05/30/17 04:56:26 PM
#3666   https://www.sec.gov/Archives/edgar/data/1228627/000114036117022538/forms3.htm BLUEVOODU 05/30/17 03:57:14 PM
#3665   GM RNN. Let's get some good news on no shorts 05/30/17 09:08:02 AM
#3664   Could be partially attributed to an analyst cutting mypekeispooped 05/27/17 02:32:58 PM
#3663   Slick sucked dropped an S3 in the AH Lone Wolf 05/26/17 04:51:55 PM
#3662   RNN buy 4.04 stocktrademan 05/26/17 11:06:18 AM
#3661   6/4/17 RX-3117 phase 2A data. If data is good no shorts 05/24/17 11:57:02 AM
#3660   This is a 15 dollar stock as each pearsby09 05/20/17 09:39:46 AM
#3659   Gaining momentum now. Looks like 4 should be no shorts 05/19/17 12:09:02 PM
#3658   What a Buy right now! 5 catalysts pearsby09 05/18/17 11:08:22 AM
#3657   Going green today imo no shorts 05/18/17 10:37:09 AM
#3656   * * $RNN Video Chart 05-12-17 * * ClayTrader 05/12/17 04:24:21 PM
#3655   It was a good ride beambe 05/12/17 03:11:39 PM
#3654   100% Agreement beambe 05/12/17 01:38:25 PM
#3653   Many know this is a 10 dollar stock pearsby09 05/12/17 01:34:38 PM
#3652   HUGE volume day pre split would =20 mill WOW ttubular 05/12/17 01:22:54 PM
#3651   Just a little Patience beambe 05/12/17 01:13:43 PM
#3650   Volume: 1,875,289 @ 12:48:26 PM ET beambe 05/12/17 01:06:19 PM
#3649   https://www.maxblue.de/maerkte-analysen/boersen-kurse/aktiendetailseite.prognose beambe 05/12/17 01:03:24 PM
#3648   I agree with all point, but I'm also Lone Wolf 05/12/17 12:54:52 PM
#3647   Looking strong. no shorts 05/12/17 12:39:08 PM
#3646   good VOLUME beambe 05/12/17 12:37:39 PM
#3645   Don't get caught on the Head Fakes! pearsby09 05/12/17 11:55:11 AM
#3644   May be getting out before the upcoming meeting. BLUEVOODU 05/12/17 10:33:16 AM
#3643   Presplit volume =10 mill + how Rnn go ttubular 05/12/17 10:11:23 AM
PostSubject